Form 4: Enanta Pharmaceuticals Chief Medical Officer Sells Shares to Cover Tax Obligations

Enanta Pharmaceuticals' Chief Medical Officer, Scott T. Rottinghaus, sold 866 shares of common stock to cover tax obligations related to a restricted stock unit award.

Summary

• Scott T. Rottinghaus, Chief Medical Officer of Enanta Pharmaceuticals, sold 866 shares of common stock on December 6, 2024.
• The sale was executed to cover withholding taxes due from the settlement of a restricted stock unit award granted on November 23, 2022.
• The shares were sold at a weighted-average price of $8.06, with individual transactions ranging from $7.87 to $8.22.
• Following the transaction, Rottinghaus directly owns 17,918 shares of Enanta Pharmaceuticals common stock.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction for tax purposes, which is neither positive nor negative for the company's overall performance. The sentiment is neutral to slightly positive as it indicates the executive is receiving stock based compensation.

Management Comments

• The sale was to satisfy tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the reporting person.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• Similar transactions are common across the pharmaceutical industry, where stock-based compensation is a significant part of executive pay.
• Many companies use 'sell to cover' mechanisms to manage tax liabilities for their employees.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.

Key Dates

Keywords

Enanta Pharmaceuticals, stock sale, insider trading, Form 4, Chief Medical Officer, Scott T. Rottinghaus, restricted stock unit, tax obligations